Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neurological disorders
Biotech
Merck KGaA swoops to $2B neurological disease pact with Skyhawk
Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 billion.
James Waldron
Aug 18, 2025 9:49am
Arialys presents promising data for IgG1 antibody treatment
Jun 20, 2025 5:02am
Vigil's rare brain disease drug flunks phase 2 study
Jun 4, 2025 9:45am
Oligomerix small molecule tamps down tau tangles in mice
Mar 14, 2025 12:30pm
Irish biotech's inhaled drug reduces depression in phase 2 trial
Feb 3, 2025 8:15am
Astellas pays Sangamo $20M to boost neurological gene therapies
Dec 19, 2024 7:13am
